Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The secret life of degradative lysosomes in axons: delivery from the soma, enzymatic activity, and local autophagic clearance.

Farfel-Becker T, Roney JC, Cheng XT, Li S, Cuddy SR, Sheng ZH.

Autophagy. 2019 Sep 23:1-2. doi: 10.1080/15548627.2019.1669869. [Epub ahead of print]

PMID:
31533518
2.

Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?

Farfel-Becker T, Do J, Tayebi N, Sidransky E.

Trends Neurosci. 2019 Sep;42(9):631-643. doi: 10.1016/j.tins.2019.05.010. Epub 2019 Jul 6. Review.

PMID:
31288942
3.

Neuronal Soma-Derived Degradative Lysosomes Are Continuously Delivered to Distal Axons to Maintain Local Degradation Capacity.

Farfel-Becker T, Roney JC, Cheng XT, Li S, Cuddy SR, Sheng ZH.

Cell Rep. 2019 Jul 2;28(1):51-64.e4. doi: 10.1016/j.celrep.2019.06.013.

4.

Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system.

Cheng XT, Xie YX, Zhou B, Huang N, Farfel-Becker T, Sheng ZH.

Autophagy. 2018;14(8):1472-1474. doi: 10.1080/15548627.2018.1482147. Epub 2018 Jul 23.

5.

Characterization of LAMP1-labeled nondegradative lysosomal and endocytic compartments in neurons.

Cheng XT, Xie YX, Zhou B, Huang N, Farfel-Becker T, Sheng ZH.

J Cell Biol. 2018 Sep 3;217(9):3127-3139. doi: 10.1083/jcb.201711083. Epub 2018 Apr 25.

6.

Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease.

Zigdon H, Meshcheriakova A, Farfel-Becker T, Volpert G, Sabanay H, Futerman AH.

FEBS Lett. 2017 Mar;591(5):774-783. doi: 10.1002/1873-3468.12591. Epub 2017 Feb 28.

7.

Induction of the type I interferon response in neurological forms of Gaucher disease.

Vitner EB, Farfel-Becker T, Ferreira NS, Leshkowitz D, Sharma P, Lang KS, Futerman AH.

J Neuroinflammation. 2016 May 12;13(1):104. doi: 10.1186/s12974-016-0570-2.

8.

RIPK3 as a potential therapeutic target for Gaucher's disease.

Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, Platt FM, Cox TM, Futerman AH.

Nat Med. 2014 Feb;20(2):204-8. doi: 10.1038/nm.3449. Epub 2014 Jan 19.

PMID:
24441827
9.

Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.

Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, Merrill AH Jr, Dobrenis K, Futerman AH.

Hum Mol Genet. 2014 Feb 15;23(4):843-54. doi: 10.1093/hmg/ddt468. Epub 2013 Sep 24.

10.

Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.

Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH.

Brain. 2012 Jun;135(Pt 6):1724-35. doi: 10.1093/brain/aws095. Epub 2012 May 7.

PMID:
22566609
11.

Animal models for Gaucher disease research.

Farfel-Becker T, Vitner EB, Futerman AH.

Dis Model Mech. 2011 Nov;4(6):746-52. doi: 10.1242/dmm.008185. Epub 2011 Oct 4. Review.

12.

Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease.

Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH.

Hum Mol Genet. 2011 Apr 1;20(7):1375-86. doi: 10.1093/hmg/ddr019. Epub 2011 Jan 20.

PMID:
21252206
13.

Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses.

Vitner EB, Dekel H, Zigdon H, Shachar T, Farfel-Becker T, Eilam R, Karlsson S, Futerman AH.

Hum Mol Genet. 2010 Sep 15;19(18):3583-90. doi: 10.1093/hmg/ddq273. Epub 2010 Jul 8.

PMID:
20616152
14.

No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease.

Farfel-Becker T, Vitner E, Dekel H, Leshem N, Enquist IB, Karlsson S, Futerman AH.

Hum Mol Genet. 2009 Apr 15;18(8):1482-8. doi: 10.1093/hmg/ddp061. Epub 2009 Feb 3.

PMID:
19193629

Supplemental Content

Loading ...
Support Center